Profile data is unavailable for this security.
About the company
Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
- Revenue in INR (TTM)25.22bn
- Net income in INR2.03bn
- Incorporated1984
- Employees1.28k
- LocationAarti Drugs LtdMahendra Industrial Estate,Ground Floor, Road No 29, Plot No 109-D,MUMBAI 400022IndiaIND
- Phone+91 2 224019025
- Fax+91 2 224073462
- Websitehttps://www.aartidrugs.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panacea Biotec Ltd | 6.06bn | -77.80m | 21.24bn | 1.29k | -- | -- | 84.45 | 3.51 | -1.27 | -1.27 | 98.66 | -- | -- | -- | -- | 4,694,217.00 | -- | 13.08 | -- | 19.61 | 57.70 | 48.06 | -1.35 | 30.99 | -- | -11.50 | -- | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 21.64bn | 1.78k | -- | -- | 27.45 | 1.72 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 22.27bn | 1.16bn | 21.95bn | 2.89k | 18.93 | -- | 11.29 | 0.9853 | 3.95 | 3.95 | 75.87 | -- | -- | -- | -- | 7,704,566.00 | -- | 10.26 | -- | 13.42 | 34.42 | 32.57 | 5.20 | 9.33 | -- | 10.46 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 23.48bn | 966.00 | 21.80 | -- | 15.95 | 2.70 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 17.46bn | -130.00m | 25.85bn | 2.06k | -- | -- | 17.64 | 1.48 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 25.89bn | 3.33k | 8.80 | -- | 6.18 | 1.17 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 29.38bn | 1.99k | 51.60 | 4.66 | 34.62 | 3.36 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 30.82bn | 1.11k | 25.96 | -- | 6.88 | 1.10 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 31.86bn | 1.47k | 33.59 | -- | 25.38 | 3.55 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 32.45bn | 1.33k | 16.02 | -- | 14.51 | 4.82 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Orchid Pharma Ltd | 8.11bn | 188.68m | 33.67bn | 737.00 | 178.55 | -- | 63.75 | 4.15 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 33.94bn | 1.28k | 16.85 | -- | 12.75 | 1.35 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 34.47bn | 221.00 | 72.13 | -- | 59.55 | 21.64 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 36.56bn | 194.00 | 35.42 | -- | 28.11 | 6.21 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Innova Captab Ltd | 14.97bn | 1.32bn | 38.50bn | 1.95k | 29.08 | -- | 21.87 | 2.57 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
| Sun Pharma Advanced Research Co Ltd | 531.36m | -2.68bn | 43.39bn | 316.00 | -- | -- | -- | 81.65 | -8.26 | -8.26 | 1.64 | -- | -- | -- | -- | 1,681,519.00 | -- | -60.53 | -- | -129.98 | -4.34 | -3.83 | -504.20 | -168.34 | -- | -8.82 | -- | -- | -5.00 | -1.35 | 11.55 | -- | -28.16 | -- |
Data as of Feb 17 2026. Currency figures normalised to Aarti Drugs Ltd's reporting currency: Indian Rupee INR
11.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 7.31m | 8.01% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 1.82m | 2.00% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 667.29k | 0.73% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 155.55k | 0.17% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 123.18k | 0.14% |
| Mellon Investments Corp.as of 06 Feb 2026 | 81.30k | 0.09% |
| Segall Bryant & Hamill LLCas of 31 Dec 2025 | 45.38k | 0.05% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 32.99k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 29.28k | 0.03% |
| State Street Global Advisors Ltd.as of 31 Dec 2025 | 21.36k | 0.02% |
More ▼
Data from 31 Dec 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
